Monaghan Medical Wins 2024 AARC Zenith Award
03 oct. 2024 04h00 HE
|
Monaghan Medical Corporation
Monaghan Medical Corporation has been honored with the prestigious 2024 Zenith Award from the American Association for Respiratory Care (AARC). This award
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
27 sept. 2024 09h35 HE
|
Regeneron Pharmaceuticals, Inc.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
27 sept. 2024 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
05 sept. 2024 04h00 HE
|
ENA Respiratory
New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities ...
Lungpacer Medical Announces PMA Submission for AeroPace® System
04 sept. 2024 09h00 HE
|
Lungpacer Medical USA Inc.
Lungpacer Medical today announced that its AeroPace System is under Food and Drug Administration (FDA) review in a premarket approval (PMA) application.
ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
27 août 2024 04h00 HE
|
ENA Respiratory
Advances a new formulation with improved stability in the clinicSingle ascending dose phase successfully completed, multiple ascending dose phase underway MELBOURNE, Australia, Aug. 27, 2024 (GLOBE...
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
26 août 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
03 juil. 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Monaghan Medical Corporation and Captis Continue to Partner to Improve Patient Outcomes
11 juin 2024 09h00 HE
|
Monaghan Medical Corporation
Monaghan & Captis announce a 2nd, 3-year contract. The agreement highlights the value of Monaghan, and Captis’ commitment to driving process efficiencies.